Tech Transfer eNews Blog
University-Industry Engagement Advisor

UCLA inks license for potential treatment of Parkinson’s disease

By Jesse Schwartz
Published: March 13th, 2019

The Regents of the University of California (the UC Regents) has licensed out a technology aimed at treating Parkinson’s disease (PD) to clinical-stage biopharmaceutical company Seelos Therapeutics.

Developed by a research team at UCLA, the technology relates to a family of peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein). Seelos plans to apply the technology to a clinical approach known as SLS-007. The company will initially focus on treating Parkinson’s and will further evaluate the approach in other central nervous system (CNS) disorders.

“Accumulation and aggregation of α-synuclein is a pathological hallmark of PD,” says Raj Mehra, founder and CEO of Seelos. “Reducing the levels of pathological forms of α-synuclein may alter the course of PD.”

Tim Whitaker, head of R&D at Seelos, comments, “Despite current available treatments for PD, including levodopa and deep brain stimulation, long-term outcomes for patients remain poor. With no disease-modifying treatments, and long-term use of established dopaminergic therapies resulting in both adverse events and side effects, significant need remains to develop not only a better means of restoring striatal dopamine but a safe and effective treatment that slows progression of the disease in patients with PD. If we are successful in our planned pre-clinical and future clinical studies, SLS-007 may prove to be such a treatment.”

Under the terms of the license agreement, Seelos has made an upfront payment to the UC Regents and UCLA of $100,000 and will issue future payments in the form of royalties upon successful commercialization.

Source: Globe Newswire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment